Programs & products

Third trial opened in the Phase II clinical program of IPH2201 - program rollout on track Trial conducted in the United States with leading investigator at OSU Innate Pharma SA (the “Company” -...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announced that the first patient was treated in the Phase I/II trial testing IPH2201, a first-in-class NKG2A checkpoint...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) announces that Professor Martine Bagot, Head of the Dermatology Department at the Saint-Louis Hospital in Paris and co-discoverer...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announced that the Data and Safety Monitoring Board (“DSMB”) completed its fifth assessment of the EffiKIR study and...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announced that Professor Martine Bagot, Head of the Dermatology Department at the Saint-Louis Hospital in Paris and co...

The Paoli Calmettes Institute (IPC), a private not-for-profit comprehensive cancer center in Marseille, France, has initiated a collaboration with Innate Pharma SA (Euronext Paris: FR0010331421 – IPH)...

Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) today announced that it has signed a co-development and commercialization agreement with AstraZeneca, along with MedImmune, its global biologics...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class therapeutic antibodies for the treatment of cancer and inflammatory...

Treatment stopped in one arm of the study with remaining two arms continuing as per protocol Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company...

The trial rationale and protocol were presented at the “Targeted Anticancer Therapies” congress in Paris Phase I/II of IPH2201 as a single agent will begin in the next few months Innate Pharma SA (the...